For the first-line treatment of metastatic lung adenocarcinoma without a targetable driver mutation, do you routinely add bevacizumab to the chemotherapy backbone in the absence of a contraindication to the drug?

That is a really good question. In my practice, I typically will use carboplatin plus pemetrexed for 4-6 cycles followed by maintenance pemetrexed. The addition of bevacizumab consistently improves response rates when added to chemotherapy, so if I have a patient that is symptomatic from local disea...

I agree with the above and would also add consideration for the phase II BRAIN study showing the utility of bevacizumab in the front line for patients with brain metastases.